BCMA, Human Protein
- Known as:
- BCMA, Human Protein
- Catalog number:
- z02731-1
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Genscript
- Gene target:
- BCMA Human Protein
Related genes to: BCMA, Human Protein
- Gene:
- TNFRSF17 NIH gene
- Name:
- TNF receptor superfamily member 17
- Previous symbol:
- BCMA
- Synonyms:
- BCM, CD269, TNFRSF13A
- Chromosome:
- 16p13.13
- Locus Type:
- gene with protein product
- Date approved:
- 1992-11-20
- Date modifiied:
- 2016-10-05
Related products to: BCMA, Human Protein
Related articles to: BCMA, Human Protein
- Soluble B-cell maturation antigen (sBCMA), generated by shedding of the plasma-cell receptor BCMA/TNFRSF17, is a circulating marker of plasma-cell burden in multiple myeloma (MM). We investigated whether early sBCMA kinetics capture treatment-induced changes in disease biology and predict subsequent Quality of Response (QoR) beyond free light chain (FLC)-based measures. In this prospective longitudinal study, 100 patients with newly diagnosed or relapsed MM starting treatment were evaluated at baseline, 1 month, and 6 months. sBCMA, involved FLC (iFLC), and involved-to-uninvolved FLC ratio (rFLC) were measured, and a 6-month response was assigned according to International Myeloma Working Group criteria. All biomarkers decreased significantly after treatment initiation ( < 0.0001). Across disease-status cohorts, sBCMA, but not iFLC or rFLC, differed at baseline and showed significantly different 1-month percentage reductions. Larger early decreases in sBCMA, iFLC, and rFLC were associated with deeper 6-month responses. In ordinal logistic regression including the three biomarkers dichotomized by a 50% reduction threshold at 1 month, only sBCMA remained independently associated with QoR; patients with <50% sBCMA reduction had higher odds of worse 6-month response (OR 5.44, 95% CI 1.58-18.76; = 0.007). These findings support early sBCMA kinetics as a biologically informative marker for short-term response monitoring in MM. - Source: PubMed
Publication date: 2026/06/11
Caponi LauraDel Giudice Maria LiviaUrsino SilviaBotti AliceGennari AlbertoPaolicchi AldoMorganti RiccardoBuda Gabriele - Geographic variability in the clinical efficacy of tonsillectomy for immunoglobulin A nephropathy (IgAN) suggests population-level differences in mucosal immune architecture. However, the molecular features of the tonsillar germinal center (GC) microenvironment-the central site for IgA class switching and mucosal B-cell activation-remain poorly characterized, particularly in relation to glomerular injury severity. - Source: PubMed
Publication date: 2026/05/22
Kawabe MayukoYamamoto IzumiOhki YutaroHayashi AyakaKanzaki GoMatsumoto KeiUeda HiroyukiHirano KeitaTsuboi NobuoYokoo Takashi - BCMA- or GPRC5D-directed CD3 bispecific antibodies are important T-cell-redirecting therapies for relapsed/refractory multiple myeloma (RRMM). We evaluated their efficacy, safety, and certainty of evidence. - Source: PubMed
Publication date: 2026/05/20
Li JiashunAbulaiti AinikaerLi DeyuZhao YanWahafu PaerhatiMaimaitiming MaerdanQiu ShiZhang YuxiangAn YaqinWang WenxingShi LiangquanYakufu MaihemutiShu LiLi GuohuaLiu Zhen - Chimeric antigen receptor (CAR) T-cell therapy carries a rare but critical risk of secondary CAR+ T-Cell Lymphoma (CAR-TCL), highlighting the urgent need for precise diagnostic tools. Current noninvasive imaging methods struggle to differentiate CAR-TCL from inflammatory sequelae, while biopsy presents several clinical challenges. In this study, we developed a novel positron emission tomography (PET) imaging probe, [Ga]Ga-BCMA-NOTA, by repurposing the extracellular domain of B-cell maturation antigen (BCMA-ECD) as a specific molecular recognizer for the BCMA-CAR single-chain variable fragment (scFv). Leveraging the high-affinity antigen-antibody interaction, the recombinant BCMA probe was produced with high purity (>98%) and demonstrated nanomolar affinity for the BCMA CAR scFv ( = 5.17 nM). The probe was synthesized with excellent radiochemical purity (>95%) and a good radiochemical yield (>50%). In preclinical xenograft models, [Ga]Ga-BCMA-NOTA PET/MR imaging demonstrated high and specific uptake in BCMA CAR-positive tumors (2.56 ± 0.61%ID/g), compared to negligible uptake in BCMA CAR-negative tumors (0.21 ± 0.05%ID/g), with a tumor-to-muscle (T/M) ratio of 16.0 ± 3.8. The uptake was blockable, confirming the probe's target specificity in vivo. Importantly, in a head-to-head comparison, [Ga]Ga-BCMA-NOTA provided significantly superior imaging contrast and a stronger correlation with tumor burden ( = 0.93) compared to [F]FDG ( = 0.76). This BCMA CAR scFv-specific probe offers a powerful new tool for the precise noninvasive visualization of BCMA CAR-positive malignancies, with significant clinical translational potential for ensuring the long-term safety and monitoring of CAR-T therapies. - Source: PubMed
Publication date: 2026/05/28
Zhou WenyaoMeng YuqiYan YuxinTang LijunYan JunjiePan DonghuiChen ChongyangXu YupingWang LizhenWang XinyuYang Min - B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has demonstrated substantial clinical benefit in relapsed/refractory multiple myeloma (R/R MM). Nonetheless, immune escape and therapeutic resistance remain major challenges, and the molecular features of residual disease have not been fully elucidated. - Source: PubMed
Publication date: 2026/05/14
Chen XinzhuoZhang JingjingChen HuiHuang RenhuaZhou XiaoxiaoWang HuipingXiao HaoPeng QianWu FanZhai ZhiminWang Zhitao